Dalmau M, Monasterio J, Nogués R, Picó M, Freixes J, Bruseghini L, Diez S, Andreoli R
Arzneimittelforschung. 1983;33(6):858-61.
3-Pyridinecarboxylic acid 2-[2-(4-chlorophenoxy)-2-methyl-1-oxo-propoxy]-1,3-propanediyl ester (binifibrate, Biniwas) an anti-arteriosclerotic and hypolipidaemic agent which showed an effect on microhaemorheological properties during studies in experimental animals (rat and rabbit), was administered to six hyperlipidaemic patients who suffered from circulatory disturbances in the lower limbs. The treatment with binifibrate was applied at a dosage of 3 X 600 mg/day during one month. Both subjective symptoms such as paraesthesia, dysthaesia, coldness at rest and functional weakness of movements were improved, as well as objective symptoms measured by oscillometry. The microhaemorheological analyses demonstrated a positive variation in relative parameters. The correlation between microhaemorheological parameters and clinical symptoms is discussed.
3-吡啶甲酸2-[2-(4-氯苯氧基)-2-甲基-1-氧代丙氧基]-1,3-丙二醇酯(必降脂,Biniwas)是一种抗动脉粥样硬化和降血脂药物,在对实验动物(大鼠和兔子)的研究中显示出对微血液流变学特性有影响。该药物被给予6名患有下肢循环障碍的高脂血症患者。在必降脂治疗中,给药剂量为每日3次,每次600毫克,持续1个月。诸如感觉异常、感觉障碍、静息时发冷和运动功能无力等主观症状以及通过示波测量法测量的客观症状均得到改善。微血液流变学分析表明相关参数有正向变化。本文讨论了微血液流变学参数与临床症状之间的相关性。